Protocol-driven auricular tVNS with credible research provenance — strong on EU regulatory and trial backing.
Best for users in EU markets who want protocol variety alongside Nurosym-level evidence.
Vagustim is a Turkish-developed auricular tVNS device, CE-marked and backed by a published trial base from clinical-research groups in Turkey and Germany. Hardware combines an ear clip with paired auxiliary electrodes for specific protocols (vagus only, vagus + acupoint, etc.). Less brand recognition outside the EU than Nurosym, comparable evidence depth, and a wider protocol library.
How we tested: Evidence-based assessment — scored from Vagustim Health product documentation, published independent and collaborator trials and 2026 EU market reviews. Not hands-on tested by ONDA.
CE-marked Class IIa medical device; trial base of independent and company-collaborator studies on HRV, anxiety and depression. Second to Nurosym in published evidence among ear-clip devices.
Stimulation mechanism
7.5
Auricular tVNS via tragus clip, plus paired electrode protocols. Documented stimulation parameters configurable per protocol.
Protocol flexibility
8.0
Library of protocol presets (stress, sleep, depression, anxiety, IBS), each with disclosed parameters. Stronger protocol variety than Nurosym.
Comfort and wearability
7.0
Tragus clip plus secondary electrode pads. Slightly more setup than a single ear clip; well-tolerated for 20-30 minute sessions.
Biofeedback and data
6.5
Companion app logs sessions and self-rated state; no on-device HRV.
Value
7.0
~€499 (~$540) hardware, no subscription. Mid-pack pricing for a research-backed device.
Pros
+CE-marked Class IIa medical device — EU regulatory backing
+Wider protocol library than Nurosym with disclosed parameters
+Independent and collaborator-published trial base on HRV and anxiety
+No subscription required
Cons
−Less brand recognition than Nurosym outside the EU
−Multi-electrode setup is more involved than a single ear clip
−No on-device HRV biofeedback
−Customer support and warranty processes weaker outside EU markets
Price: $540 €499 — one-time; no subscription (as of 2026-05-21)
Where it leads
Vagustim is the strongest non-Nurosym auricular tVNS device on evidence. It is CE-marked as a Class IIa medical device, and the trial base — from Turkish and German clinical-research groups — covers HRV modulation, depression, anxiety and IBS protocols. Where Nurosym ships a single, deliberately spartan programme, Vagustim layers a library of protocol presets on top of the ear clip, each with disclosed pulse parameters configurable per condition.
Where it falls short
Distribution is the constraint. Brand recognition outside the EU is thin, customer support and warranty processes vary by region, and the multi-electrode setup (tragus clip plus secondary pads for some protocols) is more involved than a single ear clip. For a first-time user that adds friction. There is no on-device HRV measurement — like every other ear-clip device here, biofeedback has to come from a paired wearable.
Who it is for
Choose Vagustim if you are in an EU market, want clinical-grade evidence comparable to Nurosym, and prefer a wider protocol library to a single deliberately constrained programme. If you are outside the EU, Nurosym’s distribution and support are more reliable. If you want fewer electrodes and a phone-app driven UX, Pulsetto is closer to that shape.
Background reading
The biology behind what these devices target — and the protocols that compound with the hardware.